{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:29:22Z","timestamp":1778797762641,"version":"3.51.4"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In vitro assays revealed that COX-2 inhibitors with CA II inhibitory potency suppressed both differentiation and activity of osteoclasts, whereas that without the potency reduced only osteoclast differentiation. However, all COX-2 inhibitors similarly suppressed bone destruction in adjuvant-induced arthritic rats, indicating that suppression of osteoclast differentiation is more effective than that of osteoclast activity for the treatment.<\/jats:p>\n               <jats:p>Introduction: Cyclooxygenase (COX)-2 and carbonic anhydrase II (CA II) are known to play important roles in the differentiation of osteoclasts and the activity of mature osteoclasts, respectively. Because several COX-2 selective agents were recently found to possess an inhibitory potency against CA II, this study compared the bone sparing effects of COX-2 selective agents with and without the CA II inhibitory potency.<\/jats:p>\n               <jats:p>Materials and Methods: Osteoclast differentiation was determined by the mouse co-culture system of osteoblasts and bone marrow cells, and mature osteoclast activity was measured by the pit area on a dentine slice resorbed by osteoclasts generated and isolated from bone marrow cells. In vivo effects on arthritic bone destruction were determined by radiological and histological analyses of hind-paws of adjuvant-induced arthritic (AIA) rats.<\/jats:p>\n               <jats:p>Results: CA II was expressed predominantly in mature osteoclasts, but not in the precursors. CA II activity was inhibited by sulfonamide-type COX-2 selective agents celecoxib and JTE-522 similarly to a CA II inhibitor acetazolamide, but not by a methylsulfone-type COX-2 inhibitor rofecoxib. In vitro assays clearly revealed that celecoxib and JTE-522 suppressed both differentiation and activity of osteoclasts, whereas rofecoxib and acetazolamide suppressed only osteoclast differentiation and activation, respectively. However, bone destruction in AIA rats was potently and similarly suppressed by all COX-2 selective agents whether with or without CA II inhibitory potency, although only moderately by acetazolamide.<\/jats:p>\n               <jats:p>Conclusions: Suppression of osteoclast differentiation by COX-2 inhibition is more effective than suppression of mature osteoclast activity by CA II inhibition for the treatment of arthritic bone destruction.<\/jats:p>","DOI":"10.1359\/jbmr.051025","type":"journal-article","created":{"date-parts":[[2006,4,26]],"date-time":"2006-04-26T13:26:28Z","timestamp":1146057988000},"page":"219-227","source":"Crossref","is-referenced-by-count":22,"title":["Suppression of Adjuvant-Induced Arthritic Bone Destruction by Cyclooxygenase-2 Selective Agents With and Without Inhibitory Potency Against Carbonic Anhydrase II"],"prefix":"10.1093","volume":"21","author":[{"given":"Mika","family":"Katagiri","sequence":"first","affiliation":[{"name":"Sensory & Motor System Medicine, Faculty of Medicine, University of Tokyo, Bunkyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Ogasawara","sequence":"additional","affiliation":[{"name":"Sensory & Motor System Medicine, Faculty of Medicine, University of Tokyo, Bunkyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuto","family":"Hoshi","sequence":"additional","affiliation":[{"name":"Sensory & Motor System Medicine, Faculty of Medicine, University of Tokyo, Bunkyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daichi","family":"Chikazu","sequence":"additional","affiliation":[{"name":"Sensory & Motor System Medicine, Faculty of Medicine, University of Tokyo, Bunkyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aishi","family":"Kimoto","sequence":"additional","affiliation":[{"name":"Drug Discovery Research, Astellas Pharma, Inc., Tsukuba, Ibaraki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Noguchi","sequence":"additional","affiliation":[{"name":"Drug Discovery Research, Astellas Pharma, Inc., Tsukuba, Ibaraki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Sasamata","sequence":"additional","affiliation":[{"name":"Drug Discovery Research, Astellas Pharma, Inc., Tsukuba, Ibaraki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun-ichi","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Bone Biology and Osteoporosis Research, Merck Research Laboratories, West Point, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideto","family":"Akama","sequence":"additional","affiliation":[{"name":"Medical Division, Pfizer Japan Inc., Shibuya, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hatsue","family":"Tazaki","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc., Takatsuki, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ung-il","family":"Chung","sequence":"additional","affiliation":[{"name":"Sensory & Motor System Medicine, Faculty of Medicine, University of Tokyo, Bunkyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Takato","sequence":"additional","affiliation":[{"name":"Sensory & Motor System Medicine, Faculty of Medicine, University of Tokyo, Bunkyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kozo","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Sensory & Motor System Medicine, Faculty of Medicine, University of Tokyo, Bunkyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Sensory & Motor System Medicine, Faculty of Medicine, University of Tokyo, Bunkyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024013019394207800_bib1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/art.1780280105","article-title":"Quantitative histologic studies on the pathogenesis of periarticular osteoporosis in rheumatoid arthritis","volume":"28","author":"Shimizu","year":"1985","journal-title":"Arthritis Rheum"},{"key":"2024013019394207800_bib2","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/rheumatology\/38.8.714","article-title":"Involvement of fibroblast growth factor-2 in joint destruction of rheumatoid arthritis patients","volume":"38","author":"Manabe","year":"1999","journal-title":"Rheumatol"},{"key":"2024013019394207800_bib3","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1002\/art.20367","article-title":"Induction of RANKL expression and osteoclast maturation by the binding of fibroblast growth factor 2 to heparan sulfate proteoglycan on rheumatoid synovial fibroblasts","volume":"50","author":"Nakano","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2024013019394207800_bib4","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4049\/jimmunol.168.1.450","article-title":"Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats","volume":"168","author":"Yamashita","year":"2002","journal-title":"J Immunol"},{"key":"2024013019394207800_bib5","first-page":"36","article-title":"The role of prostaglandins in the regulation of bone metabolism","volume":"313","author":"Kawaguchi","year":"1995","journal-title":"Clin Orthop"},{"key":"2024013019394207800_bib6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1210\/edrv.20.3.0367","article-title":"Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families","volume":"20","author":"Suda","year":"1999","journal-title":"Endocr Rev"},{"key":"2024013019394207800_bib7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/jbmr.5650040212","article-title":"Effect of arachidonic acid metabolites on bone resorption by isolated rat osteoclasts","volume":"4","author":"Fuller","year":"1989","journal-title":"J Bone Miner Res"},{"key":"2024013019394207800_bib8","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1172\/JCI118140","article-title":"Transcriptional induction of prostaglandin G\/H synthase-2 by basic fibloblast growth factor","volume":"96","author":"Kawaguchi","year":"1995","journal-title":"J Clin Invest"},{"key":"2024013019394207800_bib9","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/jbmr.5650110309","article-title":"Interleukin-4 inhibits prostaglandin G\/H synthase-2 and cytosolic phospholipase A2 induction in neonatal mouse parietal bone cultures","volume":"11","author":"Kawaguchi","year":"1994","journal-title":"J Bone Miner Res"},{"key":"2024013019394207800_bib10","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1359\/jbmr.2000.15.3.466","article-title":"Direct and indirect actions of fibroblast growth factor 2 on osteoclastic bone resorption in cultures","volume":"15","author":"Kawaguchi","year":"2000","journal-title":"J Bone Miner Res"},{"key":"2024013019394207800_bib11","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1359\/jbmr.2001.16.11.2074","article-title":"Regulation of osteoclast differentiation by fibroblast growth factor 2: Stimulation of receptor activator of nuclear factor kappaB ligand\/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors","volume":"16","author":"Chikazu","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2024013019394207800_bib12","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1172\/JCI8195","article-title":"Prostaglandin G\/H synthase-2 is required for maximal formation of osteoclast-like cells in culture","volume":"105","author":"Okada","year":"2000","journal-title":"J Clin Invest"},{"key":"2024013019394207800_bib13","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1172\/JCI118066","article-title":"Ovariectomy enhances and estrogen replacement inhibits the activity of bone marrow factors that stimulate prostaglandin production in cultured mouse calvariae","volume":"96","author":"Kawaguchi","year":"1995","journal-title":"J Clin Invest"},{"key":"2024013019394207800_bib14","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/ajhp\/57.3.225","article-title":"New drugs for the treatment of rheumatoid arthritis","volume":"57","author":"Schuna","year":"2000","journal-title":"Am J Health Syst Pharm"},{"key":"2024013019394207800_bib15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/stem.160229","article-title":"Tyro 3 receptor tyrosine kinase and its ligand, Gas6, stimulate the function of osteoclasts","volume":"18","author":"Nakamura","year":"1998","journal-title":"Stem Cells"},{"key":"2024013019394207800_bib16","doi-asserted-by":"crossref","first-page":"31444","DOI":"10.1074\/jbc.M910132199","article-title":"Fibroblast growth factor (FGF)-2 directly stimulates mature osteoclast function through activation of FGF receptor 1 and p42\/p44 MAP kinase","volume":"275","author":"Chikazu","year":"2000","journal-title":"J Biol Chem"},{"key":"2024013019394207800_bib17","doi-asserted-by":"crossref","first-page":"7376","DOI":"10.1074\/jbc.M007393200","article-title":"Mechanism of stimulation of osteoclastic bone resorption through Gas6\/Tyro 3, a receptor tyrosine kinase signaling, in mouse osteoclasts","volume":"276","author":"Katagiri","year":"2001","journal-title":"J Biol Chem"},{"key":"2024013019394207800_bib18","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/jbmr.5650050606","article-title":"Biochemical characterization of an electrogenic vacuolar proton pump in purified chicken osteoclast plasma membrane vesicles","volume":"6","author":"Bekker","year":"1990","journal-title":"J Bone Miner Res"},{"key":"2024013019394207800_bib19","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S8756-3282(02)00672-5","article-title":"Osteoclastic acidification pathways during bone resorption","volume":"30","author":"Rousselle","year":"2002","journal-title":"Bone"},{"key":"2024013019394207800_bib20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1172\/JCI113863","article-title":"Cytoplasmic pH regulation and chloride\/bicarbonate exchange in avian osteoclasts","volume":"83","author":"Teti","year":"1989","journal-title":"J Clin Invest"},{"key":"2024013019394207800_bib21","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1172\/JCI117235","article-title":"Inhibition of bone resorption in vitro by antisense RNA and DNA molecules targeted against carbonic anhydrase II or two subunits of vacuolar H+-ATPase","volume":"93","author":"Laitala","year":"1994","journal-title":"J Clin Invest"},{"key":"2024013019394207800_bib22","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1146\/annurev.bi.64.070195.002111","article-title":"Human carbonic anhydrases and carbonic anhydrase deficiencies","volume":"64","author":"Sly","year":"1995","journal-title":"Annu Rev Biochem"},{"key":"2024013019394207800_bib23","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/jbmr.5650090720","article-title":"Carbonic anhydrase II mRNA expression in individual osteoclasts under \u201cresorbing\u201d and \u201cnonresorbing\u201d conditions","volume":"9","author":"Asotra","year":"1995","journal-title":"J Bone Miner Res"},{"key":"2024013019394207800_bib24","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1021\/jm030912m","article-title":"Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-Selective celecoxib: New pharmacological opportunities due to related binding site recognition","volume":"47","author":"Weber","year":"2004","journal-title":"J Med Chem"},{"key":"2024013019394207800_bib25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0304-3959(83)90201-4","article-title":"Ethical guidelines for investigations of experimental pain in conscious animals","volume":"16","author":"Zimmermann","year":"1983","journal-title":"Pain"},{"key":"2024013019394207800_bib26","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s000110050225","article-title":"Pharmacological profile of JTE-522, a novel prostaglandin H synthase-2 inhibitor, in rats","volume":"46","author":"Matsushita","year":"1997","journal-title":"Inflamm Res"},{"key":"2024013019394207800_bib27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1084\/jem.191.2.275","article-title":"Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF\/RANKL-RANK interaction","volume":"191","author":"Kobayashi","year":"2000","journal-title":"J Exp Med"},{"key":"2024013019394207800_bib28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0021-9258(18)51011-5","article-title":"Electrometric and colorlimetric determination of carbonic anhydrase","volume":"176","author":"Wilbur","year":"1948","journal-title":"J Biol Chem"},{"key":"2024013019394207800_bib29","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/0470846658.ch16","article-title":"The molecular basis of osteoclast differentiation and activation","volume":"232","author":"Suda","year":"2001","journal-title":"Novartis Found Symp"},{"key":"2024013019394207800_bib30","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra032906","article-title":"New drugs for rheumatoid arthritis","volume":"350","author":"Olsen","year":"2004","journal-title":"N Engl J Med"},{"key":"2024013019394207800_bib31","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/art.20384","article-title":"Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis","volume":"50","author":"Herrak","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2024013019394207800_bib32","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/art.20382","article-title":"Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis","volume":"50","author":"Sims","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2024013019394207800_bib33","first-page":"551","article-title":"Rofecoxib [Vioxx, MK-0966; 4-(4\u2032-Methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles","volume":"290","author":"Chan","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"2024013019394207800_bib34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s000110050316","article-title":"Inhibitory effects of JTE-522, a novel prostaglandin H synthase-2 inhibitor, on adjuvant-induced arthritis and bone changes in rats","volume":"47","author":"Masaki","year":"1998","journal-title":"Inflamm Res"},{"key":"2024013019394207800_bib35","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/1043-6618(91)90042-V","article-title":"Carbonic anhydrase inhibitors are antiarthritic in the rat","volume":"24","author":"Nolan","year":"1991","journal-title":"Pharmacol Res"},{"key":"2024013019394207800_bib36","first-page":"486","article-title":"High performance liquid chromatographic determination of Cox-2 inhibitor rofecoxib in human plasma","volume":"101","author":"Mandal","year":"2003","journal-title":"J Indian Med Assoc"},{"key":"2024013019394207800_bib37","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1124\/dmd.30.6.684","article-title":"The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects","volume":"30","author":"Halpin","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"2024013019394207800_bib38","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis","volume":"343","author":"Bombardier","year":"2000","journal-title":"N Engl J Med"},{"key":"2024013019394207800_bib39","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"2024013019394207800_bib40","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJM200108093450607","article-title":"The coxibs, selective inhibitors of cyclooxygenase-2","volume":"345","author":"FitzGerald","year":"2001","journal-title":"N Engl J Med"},{"key":"2024013019394207800_bib41","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2174\/1389557043403792","article-title":"Cox-2 selective inhibitors, carbonic anhydrase inhibition and anticancer propaties of sulfonamides belonging to this class of pharmacological agents","volume":"4","author":"Supuran","year":"2004","journal-title":"Mini Rev Med Chem"},{"key":"2024013019394207800_bib42","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/ageing\/afh035","article-title":"Older people should NOT be prescribed \u201ccoxibs\u201d in place of conventional NSAIDs","volume":"33","author":"J\u00fcni","year":"2004","journal-title":"Age Ageing"},{"key":"2024013019394207800_bib43","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1136\/bmj.329.7471.867","article-title":"Lessons from the withdrawal of rofecoxib","volume":"329","author":"Dieppe","year":"2004","journal-title":"BMJ"},{"key":"2024013019394207800_bib44","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF01998973","article-title":"Effect of etodolac on type-II collagen-induced arthritis in mice","volume":"39","author":"Inoue","year":"1993","journal-title":"Agents Actions"},{"key":"2024013019394207800_bib45","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/art.1780300419","article-title":"Histopathologic evaluation of the effects of etodolac in established adjuvant arthritis in rats: Evidence for reversal of joint damage","volume":"30","author":"Weichman","year":"1987","journal-title":"Arthritis Rheum"},{"key":"2024013019394207800_bib46","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/BF01757360","article-title":"Meloxicam: A potent inhibitor of adjuvant arthritis in the Lewis rat","volume":"44","author":"Engelhardt","year":"1995","journal-title":"Inflamm Res"},{"key":"2024013019394207800_bib47","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0006-2952(01)00861-9","article-title":"Effects of a selective cyclooxygenase-2 inhibitor, celecoxib, on bone resorption and osteoclastogenesis in vitro","volume":"63","author":"Igarashi","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"2024013019394207800_bib48","doi-asserted-by":"crossref","first-page":"12130","DOI":"10.1016\/S0021-9258(17)38996-2","article-title":"Structure and exon to protein domain relationships of the mouse carbonic anhydrase II gene","volume":"260","author":"Venta","year":"1985","journal-title":"J Biol Chem"},{"key":"2024013019394207800_bib49","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0888-7543(87)90008-5","article-title":"Cloning, expression, and sequence homologies of cDNA for human carbonic anhydrase II","volume":"1","author":"Murakami","year":"1987","journal-title":"Genomics"},{"key":"2024013019394207800_bib50","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1210\/endo.139.8.6142","article-title":"Cloning, developmental expression, and immunohistochemistry of cyclooxygenase 2 in the endometrium during embryo implantation and gestation in the mink","volume":"139","author":"Song","year":"1998","journal-title":"Endocrinology"},{"key":"2024013019394207800_bib51","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1517\/14740338.3.2.131","article-title":"COX inhibitors and their effects on bone healing","volume":"3","author":"Gerstenfeld","year":"2004","journal-title":"Expert Opin Drug Saf"},{"key":"2024013019394207800_bib52","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0736-0266(02)00079-7","article-title":"COX-2 selective NSAID decreases bone ingrowth in vivo","volume":"20","author":"Goodman","year":"2002","journal-title":"J Orthop Res"},{"key":"2024013019394207800_bib53","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/jbm.a.30231","article-title":"Temporal effects of a COX-2-selective NSAID on bone ingrowth","volume":"72","author":"Goodman","year":"2005","journal-title":"J Biomed Mater Res A"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2FJBMR.051025","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/21\/2\/219\/56480162\/5650210203.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/21\/2\/219\/56480162\/5650210203.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:45:48Z","timestamp":1710341148000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/21\/2\/219-227\/7593364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,1]]},"references-count":53,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2006,2,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.051025","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2006,2,1]]},"published":{"date-parts":[[2006,2,1]]}}}